ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM
Abstract Number: 1108
The Needed Daily Dose of Colchicine in Patients with Familial Mediterranean Fever May Be Higher in Women, a Study on Behalf of the JIR Cohort
Miscellaneous Rheumatic & Inflammatory Diseases Poster II
10:30AM-12:30PM
Abstract Number: 1059
The Negative Impact of Physicians’ Neuroticism and Conscientiousness on Shared Decision Making in Patients with Systemic Lupus Erythematosus: The TRUMP2-SLE Project
Measures & Measurement of Healthcare Quality Poster
10:30AM-12:30PM
Abstract Number: 1126
The Outcomes of Carpal Tunnel Injections and Carpal Tunnel Surgery
Miscellaneous Rheumatic & Inflammatory Diseases Poster II
10:30AM-12:30PM
Abstract Number: 1118
The Performance of Behcet’s Disease Clinical Diagnostic Criteria in a Low Prevalence Region. A Retrospective Single Center Cohort Study
Miscellaneous Rheumatic & Inflammatory Diseases Poster II
10:30AM-12:30PM
Abstract Number: 1226
The Problem of Pain in Systemic Lupus Erythematosus: A Comprehensive Analysis of Pain Distribution Using the CHOIR Body Map and PROMIS Measures
Pain in Rheumatic Disease Including Fibromyalgia Poster
10:30AM-12:30PM
Abstract Number: 1448
The Proportion of Inflammatory Back Pain Patients with an Abnormal Sacral MRI in a Community-Based Primary Care Setting
SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster II
10:30AM-12:30PM
Abstract Number: 1195
The Relations of Analgesic Antidepressants Use to Knee or Hip Replacement Among Osteoarthritis Patients Compared to Selective Serotonin Reuptake Inhibitors in a Large Prospective Cohort
Osteoarthritis – Clinical Poster I
10:30AM-12:30PM
Abstract Number: 1262
The Relationship Between Child Opportunity Index and Burden of Pediatric Systemic Lupus Erythematosus
Pediatric Rheumatology – Clinical Poster II
10:30AM-12:30PM
Abstract Number: 1586
The Relationship Between the Presence, Quantity and Distribution of Cutaneous Telangiectasia and Other Vascular Manifestations of Systemic Sclerosis
Systemic Sclerosis & Related Disorders – Clinical Poster II
10:30AM-12:30PM
Abstract Number: 1103
The Role of Renal Dual-Energy CT in Exploring the Gouty Kidney: The RENODECT Study
Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II
10:30AM-12:30PM
Abstract Number: 0883
The Study of 62 Circulating Soluble Factors Is Able to Predict the Lack of Response to MTX Treatment in Recently Diagnosed DMARD Naïve Rheumatoid Arthritis Smoker and Non-Smoker Patients
Cytokines & Cell Trafficking Poster
10:30AM-12:30PM
Abstract Number: 1502
The Systemic Lupus International Collaborating Clinics (SLICC) Frailty Index (SLICC-FI) Predicts Hospitalizations. Data from the Almenara Lupus Cohort
SLE – Diagnosis, Manifestations, & Outcomes Poster II
10:30AM-12:30PM
Abstract Number: 1465
The Use of Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease Questionnaire to Assess Patient Perceptions of Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast in a Phase 4 Trial
SpA Including PsA – Treatment Poster II
10:30AM-12:30PM
Abstract Number: 1276
Therapeutic Drug Monitoring (TDM) of Rituximab to Predict Early B-Cell Repopulation in Children
Pediatric Rheumatology – Clinical Poster II
10:30AM-12:30PM
Abstract Number: 1060
Therapeutic Hydroxychloroquine Blood Levels Predict Lower Mean Frequency of Recurrent Acute Care Utilization in Lupus
Measures & Measurement of Healthcare Quality Poster
  • «Previous Page
  • 1
  • …
  • 45
  • 46
  • 47
  • 48
  • 49
  • …
  • 59
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology